Evidence map›Paper›PMID 36393979›Full record

ArticlePharmacogenomics and personalized medicine2022

Next-Generation Sequencing and Bioinformatics-Based Protocol for the Full-Length

Viktorija Igumnova, Agnija Kivrane, Anda Viksna, Inga Norvaisa, Renate Ranka

Open access · goldAbstract read
In one paragraph

Article in Pharmacogenomics and personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Viktorija IgumnovaMolecular Microbiology Group, Latvian Biomedical Research and Study Centre, Riga, Latvia.ORCID 0000-0002-5028-2718
Agnija KivraneMolecular Microbiology Group, Latvian Biomedical Research and Study Centre, Riga, Latvia.ORCID 0000-0002-8284-2011
Anda ViksnaDepartment of Infectology, Riga Stradins University, Riga, Latvia.
Inga NorvaisaCentre of Tuberculosis and Lung Diseases, Riga East University Hospital, Riga, Latvia.
Renate RankaMolecular Microbiology Group, Latvian Biomedical Research and Study Centre, Riga, Latvia.ORCID 0000-0002-3716-7950
Latvian Biomedical Research and Study Centre · LVRiga East University Hospital · LV

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Pharmacogenetics studies provide clinically relevant information on the identified associations between genetic variants and individual variability in drug response, which, in turn, offers great promise for guiding personalized drug therapy and clinical trial design. However, there is a lack of information concerning the evidence-based clinical annotations of specific Aim: To design and evaluate the next-generation sequencing-based method for full-length Materials and Methods: Seven gene-specific oligonucleotide primer pairs targeting overlapping Results: The sequencing data quality was sufficient for the detection of genetic variants dispersed throughout the Conclusion: Developed protocol can be applied in subpopulation-level association studies to determine whether single nucleotide variants (SNVs) or variant combinations from multiple regions of the

Indexed as

CYP2E1cytochrome P450next-generation sequencingpharmacogeneticssingle nucleotide variants

Identifiers

PMID36393979
PMCPMC9653044
OpenAlexW4308426652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.